Although studies on calcineurin inhibitor (i.e., tacrolimus, pimecrolimus) use in NP are lacking, their use for NP associated with inflammatory skin diseases, such as AD and psoriasis, may be attempted based on experience with CP (Pereira and Ständer, 2017). This evidence concerns the gene CP and psoriasis.